Product Description: Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects[1].
Applications: Neuroscience-Neuromodulation
Formula: N/A
References: [1]Schaefer M, et al. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J Mol Biol. 2019 Dec 6;431(24):4817-4833.
CAS Number: 2056878-75-0
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Cardiovascular Disease
Solubility: 10 mM in DMSO
Target: Factor Xa